Central nervous system activity of first-line osimertinib in epidermal growth factor receptor-mutant advanced non-small cell lung cancer.
作者信息
Liam Chong-Kin
机构信息
Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
出版信息
Ann Transl Med. 2019 Feb;7(3):61. doi: 10.21037/atm.2018.12.68.
Abstract
摘要
相似文献
1
Central nervous system activity of first-line osimertinib in epidermal growth factor receptor-mutant advanced non-small cell lung cancer.一线奥希替尼在表皮生长因子受体突变的晚期非小细胞肺癌中的中枢神经系统活性
Ann Transl Med. 2019 Feb;7(3):61. doi: 10.21037/atm.2018.12.68.
2
A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group.AME肺癌协作组关于奥希替尼在非小细胞肺癌中作用的共识。
J Thorac Dis. 2018 Jul;10(7):3909-3921. doi: 10.21037/jtd.2018.07.61.
3
Mechanisms of resistance to osimertinib.对奥希替尼的耐药机制。
J Thorac Dis. 2020 May;12(5):2851-2858. doi: 10.21037/jtd.2019.08.30.
4
An advanced non-small cell lung cancer patient with epidermal growth factor receptor sensitizing mutation responded to toripalimab in combination with chemotherapy after resistance to osimertinib: a case report.一名晚期非小细胞肺癌患者，表皮生长因子受体敏感突变，在对奥希替尼耐药后，接受托瑞帕利单抗联合化疗有效：病例报告
Transl Lung Cancer Res. 2020 Apr;9(2):354-359. doi: 10.21037/tlcr.2020.02.09.
5
6
Role of epidermal growth factor receptor-tyrosine kinase inhibitors in the management of central nervous system metastases in epidermal growth factor receptor mutation-positive nonsmall cell lung cancer patients.表皮生长因子受体-酪氨酸激酶抑制剂在表皮生长因子受体突变阳性非小细胞肺癌患者中枢神经系统转移管理中的作用
Indian J Cancer. 2017 Dec;54(Supplement):S37-S44. doi: 10.4103/ijc.IJC_532_17.
7
Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?我们能否确定表皮生长因子受体酪氨酸激酶抑制剂治疗表皮生长因子受体突变的非小细胞肺癌的最佳用药顺序？
Curr Opin Oncol. 2017 Mar;29(2):89-96. doi: 10.1097/CCO.0000000000000350.
8
Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).优化表皮生长因子受体（EGFR）突变阳性非小细胞肺癌（NSCLC）中酪氨酸激酶抑制剂（TKI）的治疗顺序。
Lung Cancer. 2019 Nov;137:113-122. doi: 10.1016/j.lungcan.2019.09.017. Epub 2019 Sep 23.
9
Complete Remission of Multiple Brain Metastases in a Patient with -Mutated Non-Small-Cell Lung Cancer Treated with First-Line Osimertinib without Radiotherapy.一名携带 - 突变的非小细胞肺癌患者在一线使用奥希替尼治疗且未接受放疗的情况下多发脑转移完全缓解。
Case Rep Oncol Med. 2020 Mar 19;2020:9076168. doi: 10.1155/2020/9076168. eCollection 2020.
10
First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option?表皮生长因子受体（EGFR）突变的非小细胞肺癌一线治疗：是否存在最佳选择？
Front Oncol. 2018 Apr 10;8:94. doi: 10.3389/fonc.2018.00094. eCollection 2018.
引用本文的文献
1
Osimertinib-Induced Hepatitis Following Immunotherapy in a Patient with Lung Adenocarcinoma Harboring De Novo EGFR Exon 19 Deletion and T790M Mutations: A Case Report.奥希替尼诱导的免疫治疗后肝炎：1例伴有新发表皮生长因子受体（EGFR）外显子19缺失和T790M突变的肺腺癌患者的病例报告
Reports (MDPI). 2025 Jun 26;8(3):101. doi: 10.3390/reports8030101.
2
*Mechanisms of circular RNA in drug resistance of lung cancer: therapeutic targets, biomarkers, and future research directions.环状RNA在肺癌耐药中的机制：治疗靶点、生物标志物及未来研究方向
Discov Oncol. 2025 May 23;16(1):896. doi: 10.1007/s12672-025-02713-x.
3
Computed tomography-based radiomics and clinical-genetic features for brain metastasis prediction in patients with stage III/IV epidermal growth factor receptor-mutant non-small-cell lung cancer.基于计算机断层扫描的放射组学和临床遗传特征预测 III/IV 期表皮生长因子受体突变型非小细胞肺癌脑转移。
Thorac Cancer. 2024 Sep;15(27):1919-1928. doi: 10.1111/1759-7714.15410. Epub 2024 Aug 5.
4
Post-Progression Analysis of -Mutant NSCLC Following Osimertinib Therapy in Real-World Settings.奥希替尼治疗真实世界环境中EGFR突变型非小细胞肺癌进展后的分析
Cancers (Basel). 2024 Jul 19;16(14):2589. doi: 10.3390/cancers16142589.
5
A non-enhancing, T2 fluid-attenuated inversion recovery hyperintense, diffusion-restricting brainstem lesion in an EGFR tyrosine kinase inhibitor-treated non-small-cell lung cancer patient.一名表皮生长因子受体酪氨酸激酶抑制剂治疗的非小细胞肺癌患者，脑部存在一处非增强、T2 液体衰减反转恢复高信号、弥散受限的脑干病变。
Biomark Med. 2024;18(9):431-439. doi: 10.1080/17520363.2024.2342231. Epub 2024 May 24.
6
Clinical Management of Patients with Non-Small Cell Lung Cancer, Brain Metastases, and Actionable Genomic Alterations: A Systematic Literature Review.非小细胞肺癌脑转移及可操作基因组改变患者的临床处理：系统文献回顾。
Adv Ther. 2024 May;41(5):1815-1842. doi: 10.1007/s12325-024-02799-9. Epub 2024 Mar 21.
7
Measured Steps: Navigating the Path of Oligoprogressive Lung Cancer with Targeted and Immunotherapies.实测步骤：借助靶向治疗和免疫疗法探索寡进展性肺癌的治疗之路
Curr Oncol Rep. 2024 Jan;26(1):80-89. doi: 10.1007/s11912-023-01490-6. Epub 2024 Jan 2.
8
EGFR is a potential dual molecular target for cancer and Alzheimer's disease.表皮生长因子受体是癌症和阿尔茨海默病的潜在双重分子靶点。
Front Pharmacol. 2023 Aug 2;14:1238639. doi: 10.3389/fphar.2023.1238639. eCollection 2023.
9
Treatment Patterns, Testing Practices, and Outcomes in Patients with Mutation-Positive Advanced Non-Small-Cell Lung Cancer in Poland: A Descriptive Analysis of National, Multicenter, Real-World Data from the REFLECT Study.波兰突变阳性晚期非小细胞肺癌患者的治疗模式、检测实践及结局：来自REFLECT研究的全国多中心真实世界数据的描述性分析
Cancers (Basel). 2023 Mar 3;15(5):1581. doi: 10.3390/cancers15051581.
10
Mutational Damages in Malignant Lung Tumors.恶性肺肿瘤中的突变损伤。
Asian Pac J Cancer Prev. 2023 Feb 1;24(2):709-716. doi: 10.31557/APJCP.2023.24.2.709.
本文引用的文献
1
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.未经治疗的表皮生长因子受体（EGFR）突变型晚期非小细胞肺癌患者中，中枢神经系统（CNS）对奥希替尼与标准表皮生长因子受体酪氨酸激酶抑制剂的反应。
J Clin Oncol. 2018 Aug 28:JCO2018783118. doi: 10.1200/JCO.2018.78.3118.
2
CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).奥希替尼治疗 T790M 阳性晚期非小细胞肺癌患者的中枢神经系统疗效：一项随机 III 期试验（AURA3）的数据。
J Clin Oncol. 2018 Sep 10;36(26):2702-2709. doi: 10.1200/JCO.2018.77.9363. Epub 2018 Jul 30.
3
CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials.CNS 反应与奥希替尼在 T790M 阳性晚期 NSCLC 患者中的作用：两项 II 期试验的汇总数据。
Ann Oncol. 2018 Mar 1;29(3):687-693. doi: 10.1093/annonc/mdx820.
4
Role of epidermal growth factor receptor-tyrosine kinase inhibitors in the management of central nervous system metastases in epidermal growth factor receptor mutation-positive nonsmall cell lung cancer patients.表皮生长因子受体-酪氨酸激酶抑制剂在表皮生长因子受体突变阳性非小细胞肺癌患者中枢神经系统转移管理中的作用
Indian J Cancer. 2017 Dec;54(Supplement):S37-S44. doi: 10.4103/ijc.IJC_532_17.
5
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.奥希替尼治疗未经治疗的 EGFR 突变型晚期非小细胞肺癌。
N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18.
6
High probability and frequency of EGFR mutations in non-small cell lung cancer with brain metastases.脑转移的非小细胞肺癌中 EGFR 突变的高概率和高频率。
J Neurooncol. 2017 Nov;135(2):413-418. doi: 10.1007/s11060-017-2590-x. Epub 2017 Aug 5.
7
Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.酪氨酸激酶抑制剂初治表皮生长因子受体突变型非小细胞肺癌脑转移的管理：一项回顾性多机构分析。
J Clin Oncol. 2017 Apr 1;35(10):1070-1077. doi: 10.1200/JCO.2016.69.7144. Epub 2017 Jan 23.
8
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.奥希替尼或铂类培美曲塞用于治疗表皮生长因子受体T790M阳性肺癌
N Engl J Med. 2017 Feb 16;376(7):629-640. doi: 10.1056/NEJMoa1612674. Epub 2016 Dec 6.
9
The role of local ablative therapy in oligometastatic non-small-cell lung cancer: hype or hope.局部消融治疗在寡转移非小细胞肺癌中的作用：炒作还是希望？
Future Oncol. 2016 Dec;12(23):2713-2727. doi: 10.2217/fon-2016-0219. Epub 2016 Jul 28.
10
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.在 EGFR 突变型 NSCLC 脑转移模型中奥希替尼与其他 EGFR-TKIs 的临床前比较，以及临床脑转移活性的早期证据。
Clin Cancer Res. 2016 Oct 15;22(20):5130-5140. doi: 10.1158/1078-0432.CCR-16-0399. Epub 2016 Jul 19.
Zotero 插件